← Back to Search

Monoclonal Antibodies

SAR439459 for Osteogenesis Imperfecta

Phase 1
Recruiting
Research Sponsored by Sanofi
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who are clinically categorized as Type I or IV osteogenesis imperfecta with a previously documented pathogenic genetic variant in COL1A1 or COL1A2.
Body weight ≥30.0 kg.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial tests SAR439459, a medicine that blocks certain proteins, in adults with Osteogenesis Imperfecta. The goal is to see if it can safely improve bone strength and density over several months.

Who is the study for?
Adults with Osteogenesis Imperfecta (OI) types I or IV, who've had at least one bone fracture in the past decade or two since turning 18. They must weigh over 30 kg and not be pregnant, breastfeeding, or donating sperm. Participants need a documented genetic variant in COL1A1/COL1A2 and must consent to the study.
What is being tested?
The trial is testing SAR439459, an antibody targeting TGFβ, given once via IV to see if it's safe and how it affects people with OI. It includes checking for side effects, how the body processes the drug (PK), its impact on bones (PD), bone density through DXA scans, and blood biomarkers over six months.
What are the potential side effects?
Potential side effects are not specified but will be monitored throughout the trial. These may include typical reactions to monoclonal antibodies such as infusion-related reactions, immune system changes affecting organs' function, allergic responses or other unforeseen issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have Type I or IV osteogenesis imperfecta with a known genetic cause.
Select...
My body weight is at least 30 kg.
Select...
I have had at least one bone fracture in the last 10 years or two since turning 18.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SAR439459Experimental Treatment1 Intervention
Participants will receive a single dose of SAR439459
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive a single dose of placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SAR439459
2017
Completed Phase 1
~170

Find a Location

Who is running the clinical trial?

SanofiLead Sponsor
2,199 Previous Clinical Trials
4,036,263 Total Patients Enrolled
Clinical Sciences & OperationsStudy DirectorSanofi
872 Previous Clinical Trials
2,020,768 Total Patients Enrolled

Media Library

SAR439459 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05231668 — Phase 1
Osteogenesis Imperfecta Research Study Groups: SAR439459, Placebo
Osteogenesis Imperfecta Clinical Trial 2023: SAR439459 Highlights & Side Effects. Trial Name: NCT05231668 — Phase 1
SAR439459 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05231668 — Phase 1
~5 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top